Back to Research Hub
Stoke Therapeutics, Inc.
STOK
$29.37+0.37 (+1.28%)
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.
StreetsValue research for Stoke Therapeutics, Inc. (STOK)
Members get the full report for Stoke Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.